Fulcher, Gregory R. http://orcid.org/0000-0001-8782-0420
Jarlov, Henrik
Piltoft, Johanne Spanggaard
Singh, Kiran Pal
Liu, Lei
Mohamed, Mafauzy
Nicodemus, Nemencio Almare Jr
Al-Jaser, Saleh Jaser
Kok, Adri
Article History
Received: 12 June 2021
Accepted: 16 September 2021
First Online: 12 October 2021
Change Date: 17 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12020-021-02956-y
Compliance with ethical standards
:
: G.R.F. has received honoraria, teaching and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Janssen, MSD, Novartis, Novo Nordisk and Sanofi-Aventis. H.J., J.S.P. and L.L. are employees of and hold shares at Novo Nordisk. K.P.S. has no conflicts of interests to disclose. M.M. received research contracts from Novo Nordisk and Eli Lilly and is a member of the local advisory board for Novo Nordisk, Eli Lilly and Sanofi. N.A.N. is a member of the local advisory board of Novo Nordisk, AstraZeneca, Merck and Torrent and received speaker honoraria from Novo Nordisk, AstraZeneca, Merck, Torrent, Eli Lilly, Sanofi, LRI-Therapharma and Servier. S.J.A.-J. has no conflicts of interests to disclose. A.K. has been involved in various advisory boards for Abbott, Adcock Ingram, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Pfizer and Sanofi and is a speaker panel member for Abbott, Aspen–GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pharmaplan, Pfizer and Sanofi and is involved in research with AstraZeneca, Merck Sharp & Dohme, Novo Nordisk and Pfizer. A.K. has received speaker or consulting honoraria from Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Sanofi, Amgen, Abbott, GlaxoSmithKline and Servier. A.K. served as a consultant and speaker panel member for Novo Nordisk.
: Written informed patient consent will be obtained prior to participation in the study.
: The study results will be communicated through abstract submission and presentation at national and international conferences and will be submitted for publication in peer-reviewed scientific and medical journals. Approvals from Institutional Review Board (IRB)/Independent Ethics Committee (IEC) (or other appropriate bodies as required locally) were obtained prior to study initiation.
Free to read: This content has been made available to all.